CARDIOME PHARMA
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
CARDIOME PHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
1986-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.cardiome.com
Total Employee:
51+
Status:
Active
Contact:
1231231234
Total Funding:
57.01 M USD
Technology used in webpage:
SPF Google Font API Font Awesome Microsoft Exchange Online Office 365 Mail JsDelivr Cloudflare JS CDN JS GoDaddy DNS JQuery CDN
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2013-11-19 | Correvio | Correvio acquired by Cardiome Pharma | N/A |
Investors List
CRG
CRG investment in Post-IPO Debt - Cardiome Pharma
Official Site Inspections
http://www.cardiome.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cardiome Pharma"
Cardiome Pharma - Crunchbase Company Profile
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. โฆSee details»
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic ...
Mar 20, 2018 Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for โฆSee details»
Cardiome Pharma Corp. - Vancouver, Canada - bionity.com
Aug 13, 2008 Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous โฆSee details»
Correvio Pharma Corp Completes Strategic Transaction with
May 15, 2018 NASDAQ: CRME TSX: COM Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital. VANCOUVER, May 15, 2018 โฆSee details»
Cardiome Pharma Corp., Vancouver, British Columbia
Cardiome Pharma Corp. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cardiome Pharma Corp. of Richmond, BC. Get the latest business insights from Dun & Bradstreet.See details»
Cardiome Pharma - Funding, Financials, Valuation & Investors
Cardiome Pharma is registered under the ticker FRA:72R . Cardiome Pharma is funded by CRG. Cardiome Pharma has acquired Correvio on Nov 19, 2013. Unlock for free . ... How much โฆSee details»
Health Canada Accepts Cardiome's Xydalba New Drug Submission โฆ
Mar 22, 2018 Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). ... Organization Profile. Cardiome Pharma Corp. Contact Cision. 866 โฆSee details»
Cardiome Sells its Canadian Business Portfolio for $25.5 Million ...
May 22, 2018 Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital. Vancouver, BC, May 22, 2018--(T-Net)--Correvio โฆSee details»
Cardiome To Acquire Correvio LLC - Fierce Biotech
Nov 19, 2013 Conference Call. Cardiome will hold a teleconference and webcast to discuss the acquisition of Correvio at 5:00pm EST (2:00pm Pacific) on Monday, November 18th, 2013.See details»
Cardiome Makes B.C. Pharma History - BC Business
Jul 7, 2010 Doug Janzen, president and CEO of Cardiome Pharma, saw his company's revenues skyrocket in 2009. Cardiome Pharma Corp.โs headquarters leave no question as to โฆSee details»
Cipher Pharmaceuticals and Cardiome Pharma Announce $25.5M โฆ
Mar 22, 2018 Cipher Pharmaceuticals and Cardiome Pharma Announce $25.5M Strategic Transaction for Canadian Business Portfolio of Cardiome. Vancouver, BC, March 22, 2018- โฆSee details»
Cardiome Announces Commercial Launch of BRINAVESS
Jun 12, 2017 Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). ... Organization Profile. Cardiome Pharma Corp. Contact Cision. 866-245 โฆSee details»
CARDIOME AND ASTELLAS ANNOUNCE REGULATORY UPDATE
Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute ... The organization is committed to becoming a global category leader in focused areas โฆSee details»
Cardiome, EnWave, Allon scoop biotech awards - Business in โฆ
Jun 6, 2011 (TSX-V: ENW) have won Gold Leaf awards from Canadaโs national biotechnology industry organization, BIOTECanada. Cardiome was recognized as company of the year, โฆSee details»
Cardiome's Biotech Bombshell - BC Business
Jul 1, 2009 When people look back at the few bombshell deals in the Canadian biotech industry this decade, expect to hear a lot about Cardiome-Merck. In April pharmaceutical giant Merck & โฆSee details»
Cardiome Announces Health Canada Approval of AGGRASTAT
Jul 17, 2017 Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). ... Organization Profile. Cardiome Pharma Corp. Contact Cision. 866-245 โฆSee details»
Cardiome Pharma Corp (CRME-Q) Stock Price and News
Real-time Price Updates for Cardiome Pharma Corp (CRME-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»
Cardiome shaken by FDA no-go on heart drug refiling
Aug 22, 2017 Cardiome's frustration is understandable given the struggles it has had trying to get Brinavess through the U.S. regulatory pathway. The drug was first filed for approval in โฆSee details»
Cardiome Reports Changes To Senior Management Team
May 16, 2017 NASDAQ: CRMETSX: COM VANCOUVER, May 16, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME /TSX: COM) today announced a number of changes to its โฆSee details»